Literature DB >> 4030286

Chemotherapeutic agents in pulmonary tuberculosis with special reference to isoniazid-ethambutol continuation therapy.

A W Lees.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030286     DOI: 10.1007/bf02938291

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  8 in total

Review 1.  The chemotherapy of pulmonary tuberculosis: a review.

Authors:  W Fox
Journal:  Chest       Date:  1979-12       Impact factor: 9.410

2.  Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong.

Authors:  M Aquinas; W G Allan; P A Horsfall; P K Jenkins; W Hung-Yan; D Girling; R Tall; W Fox
Journal:  Br Med J       Date:  1972-03-25

3.  Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again.

Authors:  G Danan; D Pessayre; D Larrey; J P Benhamou
Journal:  Lancet       Date:  1981-11-07       Impact factor: 79.321

4.  Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.

Authors: 
Journal:  Lancet       Date:  1976-11-20       Impact factor: 79.321

5.  Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1979-04

6.  Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.

Authors:  D E Snider; J Rogowski; M Zierski; E Bek; M W Long
Journal:  Am Rev Respir Dis       Date:  1982-02

7.  Short-course chemotherapy of tuberculosis with largely twice-weekly isoniazid-rifampin.

Authors:  A K Dutt; L Jones; W W Stead
Journal:  Chest       Date:  1979-04       Impact factor: 9.410

8.  Ethambutol plus isoniazid compared with rifampicin plus isoniazid in antituberculosis continuation treatment.

Authors:  A W Lees; G W Allan; J Smith; W F Tyrrell
Journal:  Lancet       Date:  1977-06-11       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.